Table 1.
Clinicopathological data of the patients included in the study.
| Variable | Patients Characteristics |
|---|---|
| n = 60 | |
| Age | |
| ≤50 | 16 (26.67%) |
| >50 | 44 (73.33%) |
| Grading | |
| G1 | 7 (11.67 %) |
| G2 | 32 (53.33%) |
| G3 | 20 (33.33%) |
| NA | 1 (1.67%) |
| Ki-67 | |
| ≤20 | 22 (36.67%) |
| >20 | 37 (61.67%) |
| NA | 1(1.67%) |
| Molecular Subtype | |
| Luminal A | 18 (30%) |
| Luminal B | 28 (46.67%) |
| HER2+ | 3 (5%) |
| TNBC 1 | 8 (13.33%) |
| NA 2 | 3(5%) |
| Tumour size (c 3) | |
| cT1 | 6 (10%) |
| cT2 | 29 (8.33%) |
| cT3 | 8 (13.33%) |
| cT4 | 11 (18.33%) |
| NA | 6 (10%) |
| Lymph nodes (c) | |
| cN0 | 15 (25%) |
| cN1 | 15 (25%) |
| cN2 | 21 (35%) |
| cN3 | 3 (5%) |
| NA | 6 (10%) |
| Metastasis (c) | |
| cM0 | 49 (81.67%) |
| cM1 | 1 (1.67%) |
| NA | 10 (16.67%) |
| Clinical stage | |
| Stage I | 5 (8.33%) |
| Stage II | 19 (31.67%) |
| Stage III | 27 (45%) |
| Stage IV | 1 (1.67%) |
| NA | 8 (13.33%) |
| Tumour size (p 4) | |
| pT0 | 7 (11.67%) |
| pT1 | 23 (38.33%) |
| pT2 | 18 (30%) |
| pT3 | 1 (1.67) |
| NA | 11 (18.33%) |
| Lymph nodes (p) | |
| pN0 | 26 (43.33%) |
| pN1 | 13 (21.67%) |
| pN2 | 8 (13.33%) |
| pN3 | 4 (6.67%) |
| NA | 9 (15%) |
| Lymphatic invasion (p) | |
| L0 | 30 (50%) |
| L1 | 21 (35%) |
| NA | 9 (15%) |
| n = 49 | |
| Neoadjuvant therapy | |
| Only CT 5 | 32 (65.31%) |
| Only ET 6 | 7 (14.29%) |
| CT + HT | 3 (6.12%) |
| Combinatory CT/ET/RTE 7 | 2 (4.08%) |
| Her2+ TT 8 | 4 (8.16%) |
| NA | 1 (2.04%) |
| Miller–Payne system | |
| Grade 1 | 14 (28.57%) |
| Grade 2 | 4 (8.16%) |
| Grade 3 | 13 (26.53%) |
| Grade 4 | 5 (10.2%) |
| Grade 5 | 8 (16.33%) |
| NA | 5 (10.2%) |
| RCB 9 | |
| RCB 0 | 8 (16.33%) |
| RCB-I | 5 (10.2%) |
| RCB-II | 15 (30.61%) |
| RCB-III | 16 (32.65%) |
| NA | 5 (10.2%) |
1 TNBC—triple negative breast cancer, 2 NA—nonassessable, 3 c—clinic, 4 p—pathologic, 5 CT—chemotherapy, 6 HT—hormonal therapy, 7 RTE—external radiotherapy, 8 TT—targeted therapy, 9 RCB—residual cancer burden.